OCWP
BMRN icon

Owl Creek Wealth Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Owl Creek Wealth Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$573 Sell
10
-125
-93% -$6.85K ﹤0.01% 1245
2026
Q1 		$7.63K Buy
+135
New +$7.87K ﹤0.01% 866

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Owl Creek Wealth Partners's BMRN Position: Q2 2026 in Review

Owl Creek Wealth Partners reduced its BioMarin Pharmaceuticals (BMRN) stake by 93% in Q2 2026, selling an estimated $6.85K and leaving 10 shares worth $573. The position accounts for ﹤0.01% of the portfolio, ranked #1245.

Owl Creek Wealth Partners first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. The position peaked at $7.63K in Q1 2026. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Owl Creek Wealth Partners held 10 shares of BioMarin Pharmaceuticals worth $573 as of Q2 2026.
  • Owl Creek Wealth Partners sold 125 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $6.85K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #1245 holding.
  • Owl Creek Wealth Partners first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Owl Creek Wealth Partners's BioMarin Pharmaceuticals position peaked at $7.63K in Q1 2026.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.